TrialCNS drugs2025

Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies.

Christoph U Correll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.